Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic that triggers direct caspase independent apoptosis of malignant B cells and induces antibody-dependent cell-mediated cytotoxicity. This study evaluated the safety, pharmacokinetics, and efficacy of otlertuzumab administered in combination with rituximab and bendamustine to patients with relapsed, indolent B-cell non-Hodgkin Lymphoma (NHL).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Invest New Drugs

Title: Investigational new drugs

ISSN (Electronic): 1573-0646

ISSN (Print): 0167-6997

Publication date (Electronic): Dec 2014

Volume: 32

Issue: 6

Affiliations

[1 ] Department of Medicine, University of Washington, Box 358081, 825 Eastlake Ave E.,, MS G3200, Seattle, WA, USA, agopal@u.washington.edu.

Article

Mid ID: NIHMS608603

DOI: 10.1007/s10637-014-0125-2

PMC ID: 4229440

PubMed ID: 24927856

SO-VID: 0741d7f7-d833-49db-bf48-8159a4e57cc3

History

Data availability:

Comments

Comment on this article

scite_

Cited by 6

See all cited by